January 31, 2018
Sanofi asks EMA to review drug for sleeping sickness
Sanofi has asked the European Medicines Agency (EMA) to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 31, 2018
Boehringer Ingelheim appoints new CEO
Boehringer Ingelheim has appointed new CEO Wednesday, who will replace Paul Fonteyne, as he will retire after 15 years, on December…
January 31, 2018
Nuformix wraps up pilot study for its NXP002 for treating fibrosis
Nuformix has completed pilot pre-clinical studies that further validate the potential for its NXP002 programme in successfully and safely treating…
January 31, 2018
Albiero Pharma completes public offering, $69.9 million net
Boston-based Albireo Pharma, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, has completed its public offering of…
January 30, 2018
Romastru brings Amryt’s cholesterol treatment Lojuxta to Romania and Bulgaria
Amryt has signed an exclusive distribution agreement for Lojuxta (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL (Romastru), a…
January 30, 2018
Beximco increases profit in Q2 2017
The London-listed Bangladesh-based pharmaceutical company, Beximco, has had net sales in the second quarter increased 12.8% to BDT 4,359.9m /…
January 30, 2018
AB Biosciences, Shire in licence deal
AB Biosciences will grant Shire an exclusive worldwide license to develop and commercialize AB Biosciences’ pan receptor interacting molecule (PRIM)…
January 29, 2018
Sanofi buys Ablynx for €3,9 billion
Sanofi will buy Belgian Nanobody technology specialist Ablynx for €3.9 billion, it was announced Monday by both companies.
January 29, 2018
Bormioli Pharma packaging innovations finds solution to unstable drug formulations
This year’s Pharmapack Conference sees Bormioli Pharma, one of the world’s leading glass and plastic packaging manufacturers for the pharmaceutical sector, make a…
January 29, 2018
Santhera reports net revenues 21% up in 2017 from its lead product Raxone, amid negative opinion by CHMP for it in DMD
Santhera Pharmaceuticals has reported an increase of 21% year-on-year in net revenues to CHF 22.9 million (2016: CHF 19.0 million)…